Skip to main content

Table 2 Characteristics of the patients with pseudoprogression after two cycles of ICIs according to EORTC

From: Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study

Patient number Age (gender) Therapy 18F-FDG PET/CT findings Interval between pseudoprogression and remission (months) Death OS (months) Method for potential identification of pseudoprogression
1 50 (M) Ipilimumab/ nivolumab Generalized lymphadenopathy 2.3 Yes 26.9
2 55 (M) Ipilimumab Two newly emerging cervical lesions (one cutaneous and one subcutaneous) 1.4 No 84.4 Application of PERCIMT
3 67 (M) Ipilimumab Increase in 18F-FDG activity and volume in existing tumor lesions 6.0 No 66.7 Application of PERCIMT
4 61 (F) Ipilimumab Sarcoid-like lymphadenopathy, pneumonitis, thyroiditis 1.4 Yes 43.5 Identification of irAEs
5 61 (M) Ipilimumab Increase in 18F-FDG activity, volume and number of tumor lesions 2.3 No 96.1
  1. F, female; M, male; ICIs, immune checkpoint inhibitors; OS, overall survival; PERCIMT, PET Response Evaluation Criteria for Immunotherapy; irAEs, immune-related adverse-events